Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.43 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584992 | 0.83 | GAA (0.46) | HDAC1HDAC2HDAC3FADS1RAB9A | |
| SCHEMBL24972973 | 0.72 | HDAC1 (0.53) | HDAC1HDAC2HDAC3NCOR1KCNH2 | |
| SCHEMBL23992177 | 0.72 | HDAC1 (0.62) | HDAC1HDAC2HDAC3NCOR1 | |
| SCHEMBL24972888 | 0.72 | HDAC1 (0.55) | HDAC1HDAC2HDAC3NCOR1KCNH2 | |
| SCHEMBL1283839 | 0.71 | MAPT (0.55) | HDAC1HDAC2FADS1 | |
| SCHEMBL13050490 | 0.71 | KMT2A (0.57) | HDAC2NPC1RAB9ALMNA | |
| SCHEMBL2131564 | 0.70 | HDAC1 (0.55) | HDAC1HDAC2HDAC3 | |
| SCHEMBL4971162 | 0.70 | RAB9A (0.51) | KDRNPC1RAB9ALMNA | |
| SCHEMBL4484518 | 0.70 | RXFP1 (0.57) | NPC1RAB9A | |
| SCHEMBL25161867 | 0.70 | HDAC2 (0.44) | HDAC1HDAC2HDAC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9546165-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | KDR 1681/4885HDAC1 203/4885HDAC2 461/4885 |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | PDK1, PDK2, PDK3 | KDR 1681/4885HDAC1 203/4885HDAC2 461/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | KDR 1681/4885HDAC1 203/4885HDAC2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.